Skip to content

Task-specific Epidural Stimulation Study

Task and Physiological Specific Stimulation for Recovery of Autonomic Function, Voluntary Movement, and Standing Using Epidural Stimulation and Training After Severe Spinal Cord Injury

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03364660
Acronym
TSEPI
Enrollment
36
Registered
2017-12-06
Start date
2017-11-08
Completion date
2024-12-30
Last updated
2024-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injuries

Keywords

Epidural Stimulation, Spinal Cord Injury, Task-Specific

Brief summary

The investigators propose to understand the role of lumbosacral spinal cord epidural stimulation (scES) in recovery of autonomic nervous system function, voluntary movement, and standing in individuals with severe spinal cord injury (SCI). Thirty-six individuals with severe SCI who have cardiovascular and respiratory dysfunction and who are unable to voluntarily move the legs or stand will receive scES for cardiovascular function, voluntary movement, or standing with and/or without weight-bearing standing. Training will consist of practicing voluntary movements or standing in the presence of specific scES configurations designed for the voluntary movements of the legs and trunk (Vol-scES), or epidural stimulation configurations specific for standing (Stand-scES). Specific configurations epidural stimulation for cardiovascular function (CV-scES) will be provided during sitting and supine and during maneuvers of orthostatic or cardiovascular stress. The ability to move voluntarily, stand, as well as cardiovascular, respiratory, bladder, bowel and sexual function will be assessed in these individuals with chronic severe spinal cord injury. Quality of life and costs of health care also will be assessed.

Detailed description

Experimental Design The investigators will enroll, implant and complete the interventions in 36 research participants who have sustained a SCI in the proposed experiments. The investigators anticipate they will need to screen 108 potential research participants to enroll 36 individuals who will complete the study. This sample size will provide sufficient replication per study group (n=4) from which variance and effect size estimates for each study hypothesis can be calculated, and hypothesis tests conducted. The investigators will also select individuals to assure that there are a minimum of 25% (n=9) women to adequately represent the percentage in the SCI population. The investigators will study each cohort of patients comprehensively, and each individual will be allocated to the group interventions based on the method of minimization. Research participants will be randomized into group interventions. This novel approach of conducting repeated experiments with comprehensive assessments in a smaller cohort of patients, rather than a more traditional approach of including a large number of patients and focusing on a single outcome, will advance both clinical and scientific knowledge in this highly complex population. The investigators have found success with the smaller cohort approach because they can employ more rigorous, quantitative and sensitive outcomes that not only inform them about the potential clinical efficacy, but also provide further knowledge of the mechanisms of neural control of movement and other physiological mechanisms related to cardiovascular, respiratory, bladder, bowel and sexual function. Group A: * Vol-scES during voluntary leg movement training while sitting or lying supine (A1). * CV-scES during sitting or lying supine (A2). Group B: * Vol-scES during voluntary leg movement training + Stand-ES during stand training (B1). * CV-ES during sitting or lying supine + Stand-ES during stand training (B2).

Interventions

DEVICELong Term Epidural Stimulation for Cardiovascular Stability

Participants undergo approximately 4 months of epidural stimulation for cardiovascular stability, daily.

DEVICEAcute epidural stimulation for cardiovascular stability

Eligible participants will be implanted with 16-electrode epidural array and epidural stimulator in the spinal cord. Participants received mapping for cardiovascular stability.

DEVICEParticipants undergo approximately 4 months of epidural stimulation for voluntary movement.

Participants undergo approximately 4 months of epidural stimulation for voluntary movement 4-7 days weekly.

DEVICELong Term Epidural Stimulation for Cardiovascular Stability plus Stand Training

Participants undergo approximately 4 months of epidural stimulation for cardiovascular stability, daily. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly.

DEVICEParticipants undergo approximately 4 months of epidural stimulation for voluntary movement plus stand training.

Participants undergo approximately 4 months of epidural stimulation for voluntary movement, 4-7 days weekly. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly.

Sponsors

Christopher Reeve Paralysis Foundation
CollaboratorOTHER
University of Louisville
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years of age * Non-progressive spinal cord injury * At least 2 years post injury * Stable medical condition * Unable to voluntarily move all individual joints of the legs * Unable to stand independently * Cardiovascular dysfunction including presence of persistent low blood pressures and/or symptoms of autonomic dysreflexia and/or orthostatic hypotension and/or dysregulation in response to postural changes and/or highly variable blood pressures in a 24 hour period * Urodynamic dysfunction including dyssynergia and/or inability to void voluntarily and/or low voiding capacity * Respiratory dysfunction including at least 15% deficit in predicted pulmonary function outcomes

Exclusion criteria

* Ventilator dependent * Untreated painful musculoskeletal dysfunction, fracture or pressure sore * Untreated psychiatric disorder or ongoing drug abuse * Cardiovascular, respiratory, bladder, or renal disease unrelated to spinal cord injury * Bladder botox injections less than 12 months prior to implant * Colostomy bag, urostomy * Any implanted pump (i.e., baclofen pump, pain pump, etc) * Ongoing nicotine use * Pregnant at the time of enrollment or planning to become pregnant during the time course of the study

Design outcomes

Primary

MeasureTime frame
Recovery of autonomic control of cardiovascular function as assessed by cardiovascular assessmentsup to 20 months
Recovery of voluntary movement as assessed by functional movement assessmentsup to 20 months

Countries

United States

Contacts

Primary ContactSusan J Harkema, PhD
susan.harkema@louisville.edu502-582-7443
Backup ContactManpreet A Chopra, BAMS
manpreet.chopra@louisville.edu502-582-7443

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026